Vebicorvir associated with Increased viral suppression with in Hepatitis B infection

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2022-09-23 15:00 GMT | Update On 2022-09-23 15:01 GMT

Vebicorvir was found to increase viral suppression by altering DNA and pregenomic (pg)RNA in Hepatitis B viral infection. It was also found to be safe and tolerable when taken with nucleos(t)ide reverse transcriptase inhibitors as per a study that was published in the Journal of Hepatology.

Total suppression of the hepatitis B virus replication is necessary for finite treatment regimens. Past data has shown persistent viremia during NrtI treatment despite HBV DNA being undetectable as HBV nucleos(t)ide reverse transcriptase inhibitors (NrtIs) do not completely suppress HBV replication. HBV core inhibitors may enhance viral suppression when combined with NrtIs. Vebicorvir (VBR) is a novel inhibitor of the HBV core protein which acts by interfering with two additional steps in HBV replication than NrtIs. Hence researchers conducted a study to evaluate the efficacy and safety of the investigational core inhibitor, vebicorvir (VBR), in virologically- suppressed patients on NrtIs.

Also Read: Consumption of Black tea associated with reduced death risk due to ischemic heart disease and stroke

Non-cirrhotic, NrtI-suppressed patients with chronic HBV were randomized to VBR 300 mg once daily or matching placebo (PBO) for 24 weeks. Treatment was stratified by hepatitis B e antigen (HBeAg) status. The primary endpoint was a change from the Baseline in serum HBeAg or hepatitis B surface antigen (HBsAg) after 24 weeks.

Results

73 patients were enrolled, 47 were HBeAg positive and 26 were HBeAg negative.
In HBeAg-positive and -negative patients, there were no differences in the change from Baseline at Week 24 for HBsAg or HBeAg.
A greater proportion of patients with detectable HBV DNA at the Baseline achieved undetectable HBV DNA at Week 24 in the VBR+NrtI vs. PBO+NrtI group.
In HBeAg-positive patients, a greater change from the Baseline in HBV pregenomic (pg)RNA was observed at Week 24 with VBR+NrtI vs. PBO+NrtI.
Treatment-emergent adverse events (TEAEs) in VBR+NrtI patients included upper respiratory tract infection, nausea, and pruritus.
No serious adverse events, Grade 4 TEAEs, or deaths were reported.

Also Read: Coffee intake associated with low liver stiffness but not steatosis

Thus, the researchers concluded from their 24-week study that VBR+NrtI demonstrated a favorable safety and tolerability profile and also achieved enhanced viral suppression.

For full reading: https://doi.org/10.1016/j.jhep.2022.04.005

Yuen MF, Agarwal K, Ma X, et al. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection. J Hepatol. 2022;77(3):642-652.

Article Source : Jounral of Hepatology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr.Niharika Harsha B

Dr.Niharika Harsha B (BDS,MDS) completed her BDS from Govt Dental College, Hyderabad and MDS from Dr.NTR University of health sciences(Now Kaloji Rao University). She has 4 years of private dental practice and worked for 2 years as Consultant Oral Radiologist at a Dental Imaging Centre in Hyderabad. She worked as Research Assistant and scientific writer in the development of Oral Anti cancer screening device with her seniors. She has a deep intriguing wish in writing highly engaging, captivating and informative medical content for a wider audience. She can be contacted at editorial@medicaldialogues.in.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

3 Out of 5 Liver Cancer Cases Preventable, Says Lancet Commission; Calls for Urgent Focus on Hepatitis, Alcohol, and Obesity

2025-07-30 02:30 GMT

Vebicorvir associated with Increased viral suppression with in Hepatitis B infection

Similar News

Simple Blood Test Marker May Predict GI Cancer Risk:Study

Medical Bulletin 30/July/2025

Fatty Liver Index Predicts Hepatocellular Carcinoma Risk in T2DM Without Cirrhosis: Study

3 Out of 5 Liver Cancer Cases Preventable, Says Lancet Commission; Calls for Urgent Focus on Hepatitis, Alcohol, and Obesity

Rising FIB-4 Scores Signal Higher Risk of Liver Stiffness and Mortality in MASLD Patients: Study Shows

Medical Bulletin 28/July/2025

Celiac and Thyroid Diseases Linked to Higher Risk of Type 1 Diabetes, Especially in Youth: Study Shows

This Night-Time Snack May Alter Gut Bacteria and Support Metabolic Health: Study Finds